MaxCyte, Inc. announced it has entered into a strategic platform license (SPL) agreement with Legend Biotech. Under the terms of the SPL, Legend Biotech obtains a non-exclusive worldwide license to use MaxCyte's Flow Electroporation®? technology and ExPERT??

platform in connection with the research, clinical development and commercialization of cell-based therapeutical products (Licensed Products). In return, MaxCyte will be eligible to receive annual licensing fees and milestones from Legend Biotech during clinical development and, upon successful commercialization, is eligible to receive licensing fees and royalties on net sales of licensed products. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT??

platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Legend Biotech is MaxCyte's 28th clinical /commercial partnership overall, each partnership generates pre-commercial milestone revenue, the vast majority of which includes program-related revenue.